Lv1
54 积分 2023-11-14 加入
Joint incorporation of randomised and observational evidence in estimating treatment effects
2个月前
已完结
Cost-Effectiveness of Sacituzumab Govitecan and Physician’s Choice of Treatment in Patients with Metastatic Triple Negative Breast Cancer in Spain
3个月前
已完结
Previous Disability and Benefit of Acute Phase Therapy in Functional Prognosis of Selected Patients with Ischemic Stroke
3个月前
已完结
Cost-Effectiveness of Sacituzumab Govitecan and Physician’s Choice of Treatment in Patients with Metastatic Triple Negative Breast Cancer in Spain
4个月前
已完结
A New Bayesian Model for Survival Data with a Surviving Fraction
5个月前
已完结
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model
5个月前
已完结
Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective
5个月前
已完结
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model
6个月前
已完结
Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
7个月前
已完结
皖公网安备34019202002308
